Beam Therapeutics Inc (BEAM)

Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Acquired by Nikko Asset Management Americas Inc. - MarketBeat

MarketBeat

Short Interest in Beam Therapeutics Inc. (NASDAQ:BEAM) Increases By 6.5% - MarketBeat

MarketBeat

Beam Therapeutics Inc. (NASDAQ:BEAM) Receives $40.18 Average Target Price from Analysts - MarketBeat

MarketBeat

Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European ... - Yahoo Finance

Yahoo Finance

68,050 Shares in Beam Therapeutics Inc. (NASDAQ:BEAM) Acquired by International Assets Investment Management ... - MarketBeat

MarketBeat

Beam Therapeutics (NASDAQ:BEAM) Trading Up 10.1% - MarketBeat

MarketBeat

Cantor Fitzgerald Weighs in on Beam Therapeutics Inc.'s FY2024 Earnings (NASDAQ:BEAM) - MarketBeat

MarketBeat

We're Not Worried About Beam Therapeutics' (NASDAQ:BEAM) Cash Burn - Simply Wall St

Simply Wall St

Cantor Fitzgerald Weighs in on Beam Therapeutics Inc.'s FY2024 Earnings (NASDAQ:BEAM) - Defense World

Defense World

Analysts Issue Forecasts for Beam Therapeutics Inc.'s Q2 2024 Earnings (NASDAQ:BEAM) - Defense World

Defense World

Wedbush Brokers Boost Earnings Estimates for Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat

MarketBeat

Q3 2024 EPS Estimates for Beam Therapeutics Inc. (NASDAQ:BEAM) Lifted by Leerink Partnrs - Defense World

Defense World

Beam Therapeutics (NASDAQ:BEAM) Given New $33.00 Price Target at Barclays - Defense World

Defense World

Research Analysts Set Expectations for Beam Therapeutics Inc.'s Q2 2024 Earnings (NASDAQ:BEAM) - Defense World

Defense World

Beam Therapeutics Inc. (NASDAQ:BEAM) Shares Bought by First Horizon Advisors Inc. - Defense World

Defense World

(BEAM) Investment Analysis and Advice - Stock Traders Daily

Stock Traders Daily

Beam Therapeutics Inc. (NASDAQ:BEAM) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind ... - Yahoo Finance

Yahoo Finance

Beam Therapeutics Inc. (NASDAQ:BEAM) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind ... - Yahoo Finance

Yahoo Finance

Bridge beams put in as residents invited to watch - Yahoo New Zealand News

Yahoo New Zealand News

Beam Therapeutics (NASDAQ:BEAM) Announces Earnings Results - MarketBeat

MarketBeat

Beam Therapeutics (NASDAQ:BEAM) Price Target Lowered to $33.00 at Barclays - MarketBeat

MarketBeat

Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss - Yahoo Finance Australia

Yahoo Finance Australia

Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss - Zacks Investment Research

Zacks Investment Research

Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference - GlobeNewswire

GlobeNewswire

Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference - EIN News

EIN News

Beam Therapeutics (NASDAQ:BEAM) Stock Rating Reaffirmed by Wedbush - Defense World

Defense World

Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine - InvestorPlace

InvestorPlace

Beam Therapeutics (NASDAQ:BEAM) Rating Reiterated by Wedbush - MarketBeat

MarketBeat

Beam Therapeutics Inc (BEAM) Reports Q1 2024 Earnings: A Detailed Overview - GuruFocus.com

GuruFocus.com

Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results - Yahoo Finance

Yahoo Finance

Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results - Yahoo Finance

Yahoo Finance

Apellis (APLS) Up on Tie-up With Beam for Novel Therapies - Yahoo Movies Canada

Yahoo Movies Canada

Vestmark Advisory Solutions Inc. Makes New $2.67 Million Investment in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat

MarketBeat

Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates

Zacks Investment Research

Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Zacks Investment Research

Top 5 CRISPR Companies To Invest In (May 2024) - Securities.io

Securities.io

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Singapore News

Yahoo Singapore News

Expert Ratings For Beam Therapeutics

Benzinga

Expert Ratings For Beam Therapeutics - Beam Therapeutics (NASDAQ:BEAM) - Benzinga

Benzinga

Beam Therapeutics Stock (NASDAQ:BEAM): Investing in Cutting-Edge Gene Editing - TipRanks.com - TipRanks

TipRanks

Tracking Cathie Wood's ARK Invest 13F Portfolio - Q1 2024 Update

Seeking Alpha

Beam Therapeutics (NASDAQ:BEAM) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

Yahoo Finance

How To Trade (BEAM) - Stock Traders Daily

Stock Traders Daily

Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S - Simply Wall St

Simply Wall St

Beam Therapeutics CEO sells shares worth over $2 million - Investing.com

Investing.com

(BEAM) Long Term Investment Analysis - Stock Traders Daily

Stock Traders Daily

Is Beam Therapeutics (NASDAQ:BEAM) Too Late to the Game? - TipRanks.com - TipRanks

TipRanks

Is Beam Therapeutics (NASDAQ:BEAM) Too Late to the Game? - Markets Insider

Markets Insider

Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?

Zacks Investment Research

Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report? - Yahoo Finance

Yahoo Finance